Predicting high-flow arteriovenous fistulas and cardiac outcomes in hemodialysis patients.

J Vasc Surg

School of Clinical Medicine, Faculty of Medicine & Health, UNSW Sydney, Sydney, New South Wales, Australia; Department of Nephrology, Prince of Wales Hospital, Sydney, New South Wales, Australia.

Published: December 2024

AI Article Synopsis

  • Heart failure is prevalent among hemodialysis patients, and high flow arteriovenous fistulas (AVFs) may be a risk factor; this study aims to create a predictive model to identify patients at risk of developing high flow AVFs.
  • Using data from 366 patients, the study compared various machine learning models to predict high flow AVF development, finding that the bootstrap forest model was the most effective.
  • Results showed that while 31.4% of patients had high flow AVFs, and 24.9% developed heart failure after AVF creation, no direct correlation was found between AVF flow and the onset of heart failure or death post-creation.

Article Abstract

Background: Heart failure is common in patients receiving hemodialysis. A high-flow arteriovenous fistula (AVF) may represent a modifiable risk factor for heart failure and death. Currently, no tools exist to assess the risk of developing a high-flow AVF (>2000 mL/min). The aim of this study was to use machine learning to develop a predictive model identifying patients at risk of developing a high-flow AVF and to examine the relationship between blood flow, heart failure, and death.

Methods: Between 2011 and 2020, serial AVF blood flows were measured in 366 prevalent hemodialysis patients at two tertiary hospitals in Australia. Four prediction models (deep neural network and three separate tree-based algorithms) using age, first AVF flow, diabetes, and dyslipidemia were compared to predict high-flow AVF development. Logistic regression was used to assess the relationship between AVF blood flow, heart failure, and death.

Results: High-flow AVFs were present in 31.4% of patients. The bootstrap forest predictive model performed best in identifying those at risk of a high-flow AVF (under the curve, 0.94; sensitivity 86%; specificity 83%). Heart failure before vascular access creation was identified in 10.2% of patients with an additional 24.9% of patients developing heart failure after AVF creation. Long-term mortality after access formation was 27%, with an average time to death after AVF creation of 307.5 ± 185.6 weeks. No univariable relationship using logistic regression was noted between AVF flow and incident heart failure after AVF creation or death. Age, flow at first measurement of >1000 mL/min, time to highest AVF flow, and heart failure predicted death after AVF creation using a general linear model.

Conclusions: Predictive modelling techniques can identify patients at risk of developing high-flow AVF. No association was seen between AVF blood flow rate and incident heart failure after AVF creation. In those patients who died, time to highest AVF flow was the most important predictor of death after AVF creation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvs.2024.11.028DOI Listing

Publication Analysis

Top Keywords

heart failure
36
avf creation
24
high-flow avf
20
avf
19
avf flow
16
risk developing
12
developing high-flow
12
blood flow
12
flow heart
12
avf blood
12

Similar Publications

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS).

Sci Rep

December 2024

Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, is widely used to treat heart failure. Despite its efficacy, sacubitril/valsartan inevitably causes adverse events such as hypotension, renal dysfunction, hyperkalemia, and angioedema. Sacubitril/valsartan-associated ototoxicity is often underreported in clinical studies and real-world settings.

View Article and Find Full Text PDF

Effect of heart rate on B-type natriuretic peptide in sinus rhythm.

Sci Rep

December 2024

Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan.

B-type natriuretic peptide (BNP) levels accurately reflect the degree of cardiac overload in heart failure. Considering cardiac morphology and intracardiac pressure, including the left ventricular end-systolic volume index (LVESVI) and left ventricular end-diastolic volume index (LVEDVI), is essential for cardiac overload assessment. These indexes influence plasma BNP levels, and high heart rate is likely associated with cardiac morphology.

View Article and Find Full Text PDF

BAY 2413555 is a novel selective and reversible positive allosteric modulator of the type 2 muscarinic acetylcholine (M2) receptor, aimed at enhancing parasympathetic signaling and restoring cardiac autonomic balance for the treatment of heart failure (HF). This study tested the safety, tolerability and pharmacokinetics of this novel therapeutic option. REMOTE-HF was a multicenter, double-blind, randomized, placebo-controlled, phase Ib dose-titration study with two active arms.

View Article and Find Full Text PDF

Predicting Sarcopenia and Frailty Risk in Patients Post Heart Transplantation.

Clin Transplant

January 2025

Rehabilitation Research Center (REVAL), Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium.

Introduction: Currently, there is little evidence on the prevalence and factors associated with sarcopenia risk or frailty risk in patients post heart transplantation (HTx). The objective of this study was to analyze the influence of sociodemographic, lifestyle, physical, and psychological factors on sarcopenia and frailty risk in patients post-HTx.

Methods: 133 patients post-HTx (59.

View Article and Find Full Text PDF

Cardiogenic shock in women: From risk factors to therapy.

Kardiol Pol

December 2024

Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.

Cardiogenic shock (CS) in women is a serious cardiovascular (CV) event associated with a high mortality rate. Non-ischemic etiologies are the most common etiologies in women, such as stress-induced cardiomyopathy, peripartum/postpartum cardiomyopathy, heart failure-related CS, or CS due to myocarditis or valvular heart disease. Although not being the most common etiology in women, acute myocardial infarction is still an important one.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!